Heart Failure Patient Has 3 Normal EKGs After Stem Cell Therapy
I was diagnosed 20 years ago. My heart was stopped up. I have 11 stents in my heart. When they put in (stents) nine, ten and eleven they blocked an artery an...

By: http://www.cellmedicine.com

Read the rest here:
Heart Failure Patient Has 3 Normal EKGs After Stem Cell Therapy - Video

Article tools

Author information

Need help?

Andrea J. Mothe and Charles H. Tator

Toronto Western Research Institute and Krembil Neuroscience Centre, Toronto Western Hospital, Toronto, Ontario, Canada.

Address correspondence to: Charles H. Tator, Toronto Western Research Institute and Krembil Neuroscience Centre, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8. Phone: 416.603.5889; Fax: 416.603.5745; E-mail: charles.tator@uhn.on.ca.

Published November 1, 2012

Spinal cord injury (SCI) is a devastating condition producing great personal and societal costs and for which there is no effective treatment. Stem cell transplantation is a promising therapeutic strategy, though much preclinical and clinical research work remains. Here, we briefly describe SCI epidemiology, pathophysiology, and experimental and clinical stem cell strategies. Research in stem cell biology and cell reprogramming is rapidly advancing, with the hope of moving stem cell therapy closer to helping people with SCI. We examine issues important for clinical translation and provide a commentary on recent developments, including termination of the first human embryonic stem cell transplantation trial in human SCI.

Spinal cord injury (SCI) is a devastating condition, with sudden loss of sensory, motor, and autonomic function distal to the level of trauma. Despite major advances in the medical and surgical care of SCI patients, no effective treatment exists for the neurological deficits of major SCI (1). Current treatment includes surgery to decompress and stabilize the injury, prevention of secondary complications, management of any that do occur, and rehabilitation. Unfortunately, neurological recovery is limited, and most SCI patients still face substantial neurological dysfunction and lifelong disability. Stem cell therapy offers several highly attractive strategies for spinal cord repair, including replacement of damaged neuronal and glial cells, remyelination of spared axons, restoration of neuronal circuitry, bridging of lesion cavities, production of neurotrophic factors, antiinflammatory cytokines, and other molecules to promote tissue sparing and neovascularization, and a permissive environment for plasticity and axonal regeneration. This review builds on several excellent previous reviews (28) and discusses the incidence and pathophysiology of SCI as well as the key experimental and clinical stem cell strategies for SCI.

Worldwide, the annual incidence of SCI is 1540 cases per million people (9). In Canada, the Rick Hansen Institute estimates there are currently 85,000 people living with SCI, with more than 4,000 new cases per year (10), and in the United States, the Christopher and Dana Reeve Foundation estimates a prevalence of over 1 million patients with SCI and more than 12,000 new cases each year (11).

Read the original here:
JCI - Advances in stem cell therapy for spinal cord injury

Bone marrow is the tissue comprising the center of large bones.

It is the place where new blood cells are produced.

Bone marrow contains two types of stem cells: hemopoietic (which can produce blood cells) and stromal (which can produce fat, cartilage and bone).

There are two types of bone marrow: red marrow (also known as myeloid tissue) and yellow marrow.

Red blood cells, platelets and most white blood cells arise in red marrow; some white blood cells develop in yellow marrow.

The color of yellow marrow is due to the much higher number of fat cells.

Both types of bone marrow contain numerous blood vessels and capillaries. At birth, all bone marrow is red.

With age, more and more of it is converted to the yellow type.

Adults have on average about 2.6kg (5.7lbs) of bone marrow, with about half of it being red.

Red marrow is found mainly in the flat bones such as hip bone, breast bone, skull, ribs, vertebrae and shoulder blades, and in the cancellous ("spongy") material at the proximal ends of the long bones femur and humerus.

Read this article:
Bone marrow - Science Daily

Multiple Myeloma Stem Cell Therapy Financial Considerations - Gujarati

By: Drmeena Shah

Read more:
Multiple Myeloma Stem Cell Therapy Financial Considerations - Gujarati - Video

An interview with Roberto Bolli, MD.

University of Louisville cardiologist Roberto Bolli, MD, led the stem cell study that tested using patients' own heart stem cells to help their hearts recover from heart failure. Though that trial was preliminary, the results look promising -- and may one day lead to a cure for heart failure.

Here, Bolli talks about what this work means and when it might become an option for patients.

2012 WebMD, LLC. All rights reserved.

"Realistically, this will not come... for another three or four years, at least," Bolli says. "It may be longer, depending on the results of the next trial, of course."

Larger studies are needed to confirm the procedure's safety and effectiveness. If those succeed, it could be "the biggest advance in cardiovascular medicine in my lifetime," Bolli says.

A total of 20 patients took part in the initial study.

All of them experienced significant improvement in their heart failure and now function better in daily life, according to Bolli. "The patients can do more, there's more ability to exercise, and the quality of life improves markedly," Bolli says.

Bolli's team published its findings on how the patients were doing one year after stem cell treatment in November 2011 in the Lancet, a British medical journal.

Each patient was infused with about 1 million of his or her own cardiac stem cells, which could eventually produce an estimated 4 trillion new cardiac cells, Bolli says. His team plans to follow each patient for two years after their stem cell procedure.

The rest is here:
Heart Stem Cell Trial: Interview With Researcher Roberto Bolli, MD

As we age, the reduced turnover of our cells means we can lose control over how our skin ages. Epidermal stem cells needed to create healthy new skin are significantly reduced and function less efficiently. A discovery based on promising plant stem cell research may allow you to regain control.

Scientists have found that a novel extract derived from the stem cells of a rare apple tree cultivated for its extraordinary longevity shows tremendous ability to rejuvenate aging skin. By stimulating aging skin stem cells, this plant extract has been shown to lessen the appearance of unsightly wrinkles. Clinical trials show that this unique formulation increases the longevity of skin cells, resulting in skin that has a more youthful and radiant appearance.

Cells in our bodies are programmed for specific functions. A skin cell, a brain cell, and a liver cell all contain the same DNA, or set of genes. However, each cells fate is determined by a set of epigenetic (able to change gene expression patterns) signals that come from inside it and from the surrounding cells as well. These signals are like command tags attached to the DNA that switch certain genes on or off.

This selective coding creates all of the different kinds of cells in our bodies, which are collectively known as differentiated (specialized) cells.

Although differentiated cells vary widely in purpose and appearance, they all have one thing in common: they all come with a built-in operational limit. After so many divisions, they lose their ability to divide and must be replaced. This is where stem cells come in.

Your body also produces other cells that contain no specific programming. These stem cells are blank, so your body can essentially format them any way it pleases. Two universal aspects shared by this type of cell are: (1) the ability to replenish itself through a process of self-renewal and (2) the capacity to produce a differentiated cell.

In animals and humans, two basic kinds of stem cells exist: embryonic and adult stem cells. Embryonic stem cells have the power to change into any differentiated cell type found anywhere in your body. Adult stem cells, on the other hand, are generally more limited. They can only evolve into the specific type of cell found in the tissue where they are located. The primary function of these adult stem cells is maintenance and repair.

But certain adult stem cells found in nature retain the unlimited developmental potential that embryonic stem cells possess. These cells have become the main focus for an exciting new wave of regenerative medicine (repairing damaged or diseased tissues and organs using advanced techniques like stem cell therapy and tissue engineering).

The basal (innermost) layer of the skins epidermis comprises two basic types of cells: (1) the slowly dividing epidermal stem cells (that represent about 2-7% of the basal cell population) and (2) their rapidly dividing offspring that supply new cells to replace those that are lost or dying.1-3

The slow self-renewal process of epidermal stem cells, however, creates a problem. Because each epidermal stem cell only lasts for a certain number of divisions, and because each division runs the risk of lethal DNA mutation, the epidermal stem cell population can become depleted. When this happens, lost or dying skin cells begin to outnumber their replacements and the skins health and appearance start to decline.

See the rest here:
Apple Stem Cells Offer Hope for Aging and Damaged Skin - Life ...

Maintaining more luminous skin is dependent upon your bodys unique ability to replace dead skin cells. This vital process of continuous self-renewal depends on the activity of epidermal stem cells.

The epidermis (upper skin layer) has been shown to replace itself in just 20 days in young adults, compared to 30 days in middle-aged adults.1 Unfortunately, this rate of renewal dramatically declines after age 50.

The exciting news is that the decline in the skins capacity to renew itself may be safely slowed or even reversed.

Researchers have found that when applied to the skin, a novel, patent-pending preparation of cultured stem cells derived from the Alpine rose may stimulate epidermal stem cell activity.2

In this article, epidermal stem cells role in skin beauty is detailed, along with supportive data on Alpine rose stem cells ability to activate the skins innate power of self-renewal.

The Alpine rose (Rhododendron ferrugineum) thrives in the Swiss Alps and the Pyrenees where it endures high altitudes, extreme cold, dry air, and high levels of ultra violet radiation.

This plants ability to withstand harsh environmental stress factors such as freezing temperatures, drought, and scorching UV rays prompted researchers to investigate the Alpine rose as a source of protection for human skin cells. Like the Alpine rose, human skin cells must resist a host of environmental stressors and lock in essential fluids. Skin that performs this barrier function well is more resilient and less likely to develop fine lines and wrinkles or show other signs of aging.

The skin functions as an essential barrier to protect the body from microbial invaders, toxins, the ravages of weather, dehydration, and mechanical trauma. This protective function is governed by stem cells. There are two broad classes of stem cells: pluripotent embryonic stem cells, which have the capacity to develop into any cell type, and adult stem cells, which can differentiate to become some or all of the specialized cell types present in a specific tissue or organ. The adult stem cells in the skin reside in the deepest layer of the epidermis, close to hair follicles.

Epidermal stem cells help to facilitate the turnover of all skin cells, replenishing their supply and maintaining a continuous equilibrium of skin cells in all stages of their life cycles. Epidermal stem cells have relatively slow turnover compared to other skin cell types, but it is their tremendous reproducing potential that gives the skin the remarkable capacity to renew itself completely.3 These types of stem cells also are vitally important for repairing the skin after injury and enabling wound healing.4

The researchers found that applying selected plant stem cell extracts to the skin, specifically those cultured from the Alpine rose, offers protection to the epidermal stem cells, prolonging their lives, increasing their colony-forming efficiency and enhancing their function. These potent plant stem cells from the Alpine rose appear to stimulate the skins own epidermal stem cell activity, revitalizing it and boosting its capacity for repair and self-renewal.

Go here to see the original:
Activate Self-Renewing Skin Stem Cells - Life Extension

Introduction

The announcement of the ability to produce embryonic cell-like lines from ordinary skin cells has the news media scrambling to get feedback about the possible efficacy of such lines in stem cell therapies. Many politicians have landed on one side or the other, with liberals saying that embryonic stem cell research is still necessary1 and conservatives claiming that all embryonic research should be halted. The marketplace of science will eventually weigh-in on which method(s) are used in real therapies.

Embryonic stem cell (ESC) research has been a hot topic, with conservatives saying that such research is morally unacceptable and liberals saying that conservatives value a clump of cells more than people who have serious disabling diseases. Several groups of medical researchers (including James Thomson, the first person to culture ESC) recently showed that normal skin cells can be reprogrammed to an embryonic state, producing what are now called induced pluripotent stem (iPS) cells. Originally performed in mice in June, 2007,2 researchers took four genes OCT3/4, SOX2, KLF4, and c-MYC and incorporated those genes into the nucleus of cells to induce pluripotency. Such lines could be expanded indefinitely and could differentiate to form numerous kinds of different tissues.

Just five months after the mouse study was published, the feat was repeated by three separate laboratories using human skin cells.3 One research group used the same genes as those used in the mouse study, whereas a second group used OCT3, SOX2, NANOG and LIN28. The techniques were efficient enough to generate one cell line for every 5-10 thousand cells treated. Although not extremely efficient, it is quite usable, since it is possible to obtain hundreds of thousands to millions of cells to carry out these kinds of studies. The technique was recently replicated for adult human skin cells,4 instead of skin cell lines, demonstrating that it could be used to generate patient-specific cell lines.

Studies using iPS cell lines have shown that those cells undergo similar changes compared to what is observed with embryonic stem cells. Cell populations grew at the same rate, telomerase (which preserves the ends of chromosomes) was present in both iPS and ESC. Severalgenes that are silenced in fibroblasts, but active in ESC, were also active in the iPS cells. The iPS cell lines could be differentiated into heart muscle and neuronal cells, in addition to basic cell types (ectoderm, mesoderm, and endoderm). Gene expression assays showed that 5,000 genes from iPS cells showed a five-fold difference in expression compared to those in fibroblasts, although 1,267 genes had a five-fold difference in expression between ESC and iPS cells. According to the James Thomson study, "The human iPS cells described here meet the defining criteria we originally proposed for human ES cells (14), with the significant exception that the iPS cells are not derived from embryos."3

Originally, the new technique is not without its own set of problems, although within two years, virtually all had been resolved. One of the original genes used for reprogramming (c-MYC) has been shown to produce tumors and cancers. Obviously, it would not be a good choice for patient therapy. However, this gene was eliminated in some of the later techniques.5 The second problem was that the genes were originally introduced through the use of a retrovirus that incorporates into the host cell DNA. Depending upon where the gene sequence inserts, it may cause trouble (including mutations and cancers). Those who watched the I am Legend movie will remember that a retrovirus-derived cancer treatment was responsible for turning the surviving members of the human race into an army of grotesque monsters. Although such a transformation is not possible, the initiation of cancer in even a small number of treated patients would make such treatments unusable for human therapy. Two years later the problem of using a retroviral system for reprogramming was solved by switching to a simple lentivirus reprogramming system.6 Within weeks, other researchers went a step further, eliminating viral reprogramming altogether by using reprogramming genes (OCT4, SOX2, NANOG, LIN28, c-Myc, and KLF4) cloned into a circular piece of DNA called a plasmid.7 Subsequent culture of of the iPS over a period of weeks resulted in the complete loss of the plasmid, but with continued pluripotency. The potential of iPS cells is so great that the researcher who first grew ESC in culture is now one of the leading proponents of iPS stem cell research.

A more recent, but somewhat uncertain potential problem has been identified more recently. Since iPS cells are derived from adult tissues, they tend to harbor some of the same epigenetic profiles as those adult tissues from which they are derived. As cells age or differentiate, certain genes are turned on or off through methylation of those gene's promoters. The process prevents those cells from undergoing additional changes that might cause the cells to lose their differentiated properties. When adults cells are induced to pluripotency, some of those epigenetic profiles are retained in the iPS cells.8 How will these vestiges of adult cells affect iPS ability to differentiate into cells that are useful for disease models or therapy? At this point, we don't know for sure. However, my guess is that different ESC lines will exhibit different epigenetic profiles, as will specific isolates of iPS cells. Although researchers have found no problems in producing differentiated iPS lines, some of these epigenetic changes might interfere with the ultimate function of these cells as differentiated cell lines.

Even with these issues, research institutes are beginning to focus their stem cell research on iPS cells. Cedars-Sinai Medical Center recently opened its Induced Pluripotent Stem Cell Core Production Facility in late 2011, according to their press release.9

Induction of pluripotency to produce embryonic-like stem cells is the hot topic in stem cell research. The fact that human iPS cells have been produced in many different laboratories after the initial animal studies shows that the technique is robust and easily reproducible. In contrast, the competing technique, human somatic cell nuclear transfer (cloning), has never been transferred from animal studies to human application, despite years of attempts. At this point, it seems pretty certain that the iPS technique will soon replace ESC as the preferred means of generating human stem cell lines. However, the disadvantage of iPS cells is that the cell lines produced would be patient specific (only useful for the intended patient), whereas the establishment of ESC lines allows biotech companies to patent the lines in order to make lots of money.

http://www.godandscience.org/doctrine/reprogrammed_stem_cells.html Last Modified October 6, 2011

Link:
Induced Pluripotent Stem Cells (iPS) from Human Skin: Probable ...

Somatic stem cells (also called adult stem cells) exist naturally in the body. They are important for growth, healing, and replacing cells that are lost through daily wear and tear.

Potential as therapy Stem cells from the blood and bone marrow are routinely used as a treatment for blood-related diseases. However, under natural circumstances somatic stem cells can become only a subset of related cell types. Bone marrow stem cells, for example, differentiate primarily into blood cells. This partial differentiation can be an advantage when you want to produce blood cells; but it is a disadvantage if you're interested in producing an unrelated cell type.

Special considerations Most types of somatic stem cells are present in low abundance and are difficult to isolate and grow in culture. Isolation of some types could cause considerable tissue or organ damage, as in the heart or brain. Somatic stem cells can be transplanted from donor to patient, but without drugs that suppress the immune system, a patient's immune system will recognize transplanted cells as foreign and attack them.

Ethical considerations Therapy involving somatic stem cells is not controversial; however, it is subject to the same ethical considerations that apply to all medical procedures.

View post:
Stem Cell Quick Reference - Learn Genetics

SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- Howard Leonhardt of Leonhardt Ventures and the Cal-X Stars Innovation and Business Accelerator team will present at the 2013 World Stem Cell Summit on Friday, December 6, 2013 at the Manchester Grand Hyatt in San Diego in two sessions.

2pm Harbor Room AB - Developing Combination Products Cells, Genes, Devices

3pm Harbor Room DE - Startup Considerations for Stem Cell Companies - Getting Funding and Avoiding Pitfalls

Cal-X Stars Business Accelerator, Inc.is an innovation accelerator with an unprecedented portfolio of breakthrough cardiovascular life science and high social good impact innovations that have primarily been majority funded to date by Leonhardt Ventures and its associated angel investor network.

The innovation laboratory and business accelerator has two clearfocusareas:

Management team and board have a proven track record in leading breakthrough innovations in these focused spaces -http://www.calstockexchange.com/team-cal-x/.

Cardiovascular portfolio technologies include...

MyoStim Pacershttp:/www.myostimpacers.com- heart failure pacemaker designed to recruit reparative stem cells to damaged and weakened heart tissue.

Bioheart, Inc.http://www.bioheartinc.com- Phase III leader in applying adult muscle stem cells to treat advanced heart failuresince 1999.Only cell type known to grow new contractile muscle in the depths of heart scar tissue. In the Phase II/III MARVEL randomized, double blinded, placebo controlled study Bioheart's MyoCell achieved 95.7 meters improvement in exercise capacity over placebo (minus 4 meters).

BioPace biological pacemaker made entirely of living cells.

See the original post:
Howard Leonhardt of Leonhardt Ventures to Present at World ...

PUBLIC RELEASE DATE:

5-Dec-2013

Contact: Jennifer Nachbur jennifer.nachbur@uvm.edu 802-656-7875 University of Vermont

New research by University of Vermont Associate Professor of Medicine Jeffrey Spees, Ph.D., and colleagues has identified a new tool that could help facilitate future stem cell therapy for the more than 700,000 Americans who suffer a heart attack each year. The study appeared online in Stem Cells Express.

Stem cells, which can come from embryos, fetal tissue and adult tissues, have the potential to develop into a variety of cell types in the body, such as muscle cells, brain cells and red blood cells. These cells also possess the ability to repair human tissues. The field of regenerative medicine which explores the viability of using embryonic, fetal and adult stem cells to repair and regenerate tissues and organs has struggled to successfully graft cells from culture back into injured tissue.

"Many grafts simply didn't take; the cells wouldn't stick or would die," explains Spees. So he and his research team set out to develop ways to enhance graft success.

They focused on a type of bone marrow-derived progenitor cell that forms stromal cells. Stromal cells form connective tissue and also support the creation of blood cells. The researchers were aware of that these cells secrete a diverse array of molecules called ligands that protect injured tissue, promote tissue repair and support stem and progenitor cells in culture. Different ligands interact with specific receptors on the surface of a stem or progenitor cell, transmitting signals that can instruct the cell to adhere, to divide, or to differentiate into a mature functional cell.

To confirm whether or not these types of ligands would protect a cardiac progenitor cell and help it graft, the group isolated a conditioned medium from human bone marrow-derived progenitor cells. They found that the medium contained Connective Tissue Growth Factor (CTGF) and the hormone insulin.

"Both CTGF and insulin are protective," says Spees. "Together, they have a synergistic effect."

In the study, Spees and colleagues compared the impact of sending a cardiac stem cell "naked" into a rodent heart with infarction (heart attack) to a cell that instead wore a "backpack" of protective ligands, created by incubating about 125,000 cardiac cells in a "cocktail" of CTGF and insulin on ice for 30 minutes. The team grafted the cells sub-epicardially between the outer layer and the muscle tissue of the heart and found that their priming cocktail resulted in improved graft success.

Follow this link:
Priming 'cocktail' shows promise as cardiac stem cell grafting ...

stem cell therapy makes senile spot disappear.
"ReLife" was founded by Professor Zhang, a well respected doctor with decades of experience in the medical field. Over the decades, "ReLife" pioneering, country leading experts have been dedicated...

By: IMC ReLife

See the original post here:
stem cell therapy makes senile spot disappear. - Video

A new study appearing in STEM CELLS Translational Medicine (SCTM) demonstrates the potential of a subset of stem cell called CD34+ in treating hard to heal bone fractures.

Durham, NC (PRWEB) December 04, 2013

A new study appearing in STEM CELLS Translational Medicine (SCTM) demonstrates the potential of a subset of stem cell called CD34+ in treating hard to heal bone fractures.

While most patients recover from broken bones with little or no complication, up to 10 percent experience fractures that wont heal. This can lead to a number of debilitating side effects, from infection to bone loss, and it can require extensive treatment involving multiple operations and prolonged hospitalization as well as long-term disability.

Regenerating broken bone using stem cells could offer an answer. Adult human peripheral blood CD34+ cells have been shown to contain an abundance of a type of stem cell called endothelial progenitor cells (EPCs) as well as hematopoietic stem cells, which give rise to all types of blood cells. As such, they could be good candidates for this therapy.

However, while other types of stem cells had been tested for their bone regeneration potential, the ability of CD34+ to do so had never been reported on before the phase I/II clinical study was published in the current SCTM. It was conducted by researchers at Kobe University Graduate School of Medicine, led by Tomoyuki Matsumoto, M.D., and Ryosuke Kuroda, M.D., members of the universitys department of orthopedic surgery and its Institute of Biomedical Research and Innovation (IBRI).

The study was designed to evaluate the safety, feasibility and efficacy of autologous and G-CSF-mobilized CD34+ cells in patients with non-healing breaks, breaks that had not healed in nine months, in their legs. (G-CSF is a drug that releases stem cells from the bone marrow into the blood.) Seven patients were treated with the stem cells after receiving bone grafts.

Bone union was successfully achieved in every case, confirmed as early as 16.4 weeks on average after treatment, Dr. Kuroda said.

Dr. Matsumoto added, Neither deaths nor life-threatening adverse events were observed during the one year follow-up after the cell therapy. These results suggest feasibility, safety and potential effectiveness of CD34+ cell therapy in patients with nonunion.

Atsuhiko Kawamoto, MD, Ph.D., a collaborator in IBRI, said, "Our team has been conducting translational research of CD34+ cell-based vascular regeneration therapy mainly in cardiovascular diseases. This promising outcome in bone fracture opens a new gate of the bone marrow-derived stem cell application to other fields of medicine."

Follow this link:
Hard to heal bone fractures could benefit from CD34+ stem cell ...

Skin Doctors YouthCell Range TVC
YouthCell contains the latest plant stem cell technology (PhytoCellTec) to help delay the appearance of chronological ageing of the skin. These plant stem ...

By: Skin Doctors UK

View original post here:
Skin Doctors YouthCell Range TVC - Video

Oct. 17, 2013

A Waisman Biomanufacturing specialist examines cells in a culture in the cell therapy clean room. The UW-Madison Waisman Center opened Waisman Biomanufacturing to ease the research and development of biological products and drugs.

Photo: Waisman Biomanufacturing

Developing a new drug takes enormous amounts of time, money and skill, but the bar is even higher for a promising stem-cell therapy. Many types of cells derived from these ultra-flexible parent cells are moving toward the market, but the very quality that makes stem cells so valuable also makes them a difficult source of therapeutics.

"The ability to form many types of specialized cells is at the essence of why we are so interested in stem cells, but this pluripotency is not always good," says Derek Hei, director of Waisman Biomanufacturing, a facility in the Waisman Center at UW-Madison.

"The cells we can make from stem cells cells for the heart, brain and liver have amazing potential, but you can also end up with the wrong type of cell. If the cells are not fully differentiated, they can end up differentiating into the wrong cell type," Hei says.

Derek Hei

Just like drugs, stem cells for clinical trials must be produced under a demanding regulatory regime called "good manufacturing practice," he says. That capacity is rare in labs in private business and universities, and this is the only one at UWMadison.

Read the rest here:
Biomanufacturing center takes central role in developing stem ...

Aegean Process (Stem Cell Therapy with PRP)

By: sapardue

Original post:
Aegean Process (Stem Cell Therapy with PRP) - Video

The hearts own stem cells play their part in regeneration

Sca1 stem cells replace steadily ageing heart muscle cells

November 28, 2013

Up until a few years ago, the common school of thought held that the mammalian heart had very little regenerative capacity. However, scientists now know that heart muscle cells constantly regenerate, albeit at a very low rate. Researchers at the Max Planck Institute for Heart and Lung Research in Bad Nauheim, have identified a stem cell population responsible for this regeneration. Hopes are growing that it will be possible in future to stimulate the self-healing powers of patients with diseases and disorders of the heart muscle, and thus develop new potential treatments.

Stem cells play a part in heart regeneration. This image of the fluorescence microscope depicts a section of the heart tissue of a mouse. The green colouring of the cells in the middle shows that the cell originated from a so-called Sca1 stem cell.

MPI for Heart and Lung Research

MPI for Heart and Lung Research

Some vertebrates seem to have found the fountain of youth, the source of eternal youth, at least when it comes to their heart. In many amphibians and fish, for example, this important organ has a marked capacity for regeneration and self-healing. Some species in the two animal groups have even perfected this capability and can completely repair damage caused to heart tissue, thus maintaining the organs full functionality.

The situation is different for mammals, whose hearts have a very low regenerative capacity. According to the common school of thought that has prevailed until recently, the reason for this deficit is that the heart muscle cells in mammals cease dividing shortly after birth. It was also assumed that the mammalian heart did not have any stem cells that could be used to form new heart muscle cells. On the contrary: new studies show that aged muscle cells are also replaced in mammalian hearts. Experts estimate, however, that between just one and four percent of heart muscle cells are replaced every year.

Scientists in Thomas Brauns Research Group at the Max Planck Institute for Heart and Lung Research have succeeded in identifying a stem cell population in mice that plays a key role in this regeneration of heart muscle cells. Experiments conducted by the researchers in Bad Nauheim on genetically modified mice show that the Sca1 stem cells in a healthy heart are involved in the ongoing replacement of heart muscle cells. The Sca-1 cells increase their activity if the heart is damaged, with the result that significantly more new heart muscle cells are formed.

See more here:
Research | Research news | 2013 | The heart’s own stem cells ...

"VAMPIRE FACELIFT STEM CELL and PRP THERAPY" http://www.CLINICell.com

By: ClinicellTech

More here:
"VAMPIRE FACELIFT STEM CELL and PRP THERAPY" http://www.CLINICell.com - Video

Multiple Myeloma Stem Cell Therapy mp4

By: Drmeena Shah

See the article here:
Multiple Myeloma Stem Cell Therapy mp4 - Video

BEIJING Theyre paralyzed from diving accidents and car crashes, disabled by Parkinsons, or blind. With few options available at home in America, they search the Internet for experimental treatments and often land on Web sites promoting stem cell treatments in China.

They mortgage their houses and their hometowns hold fundraisers as they scrape together the tens of thousands of dollars needed for travel and the hope for a miracle cure.

A number of these medical tourists claim some success when they return home.

Jim Savage, a Houston quadriplegic, says he can move his right arm. Penny Thomas of Hawaii says her Parkinsons tremors are mostly gone. The parents of 6-year-old Rylea Barlett of Missouri, born with an optical defect, say she can see.

But documentation is mostly lacking, and Western doctors warn that patients are serving as guinea pigs in a country that isnt doing the rigorous lab and human tests that are needed to prove a treatment is safe and effective.

Effectiveness questioned Noting the lack of evidence, three Western doctors undertook their own limited study. It involved seven patients with spinal cord injuries who chose to get fetal brain tissue injections at one hospital in China. The study reported no clinically useful improvements even though most patients believed they were better. Five developed complications such as meningitis.

Experts in the West have theories about why some people think theyve improved when the evidence is thin. Some are often getting intensive physical therapy, along with the mysterious injections; the placebo effect may also be a factor.

John Steeves, a professor at the University of British Columbia who heads an international group that monitors spinal cord treatments, has another theory. Some patients may be influenced by the amount of money they paid and the help they got from those who donated or helped raise money.

Needless to say, when they come back, what are they going to report to their friends and neighbors? That it didnt work? said Steeves. Nobody wants to hear that.

He and other experts have written a booklet advising patients who are considering such treatments.

The rest is here:
Americans seek stem cell treatments in China - Health ...